HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia.

AbstractBACKGROUND AND AIMS:
Glucagon-like peptide-1 (GLP-1) may provide beneficial cardiovascular effects, possibly due to enhanced myocardial energetic efficiency by increasing myocardial glucose uptake (MGU). We assessed the effects of GLP-1 on MGU in healthy subjects during normo- and hypoglycemia.
MATERIALS AND METHODS:
We included eighteen healthy men in two randomized, double-blinded, placebo-controlled cross-over studies. MGU was assessed with GLP-1 or saline infusion during pituitary-pancreatic normo- (plasma glucose (PG): 4.5 mM, n = 10) and hypoglycemic clamps (PG: 3.0 mM, n = 8) by positron emission tomography with (18)fluoro-deoxy-glucose ((18)F-FDG) as tracer.
RESULTS:
In the normoglycemia study mean (± SD) age was 25±3 years, and BMI was 22.6±0.6 kg/m(2) and in the hypoglycemia study the mean age was 23±2 years with a mean body mass index of 23±2 kg/m(2). GLP-1 did not change MGU during normoglycemia (mean (+/- SD) 0.15+/-0.04 and 0.16+/-0.03 µmol/g/min, P = 0.46) or during hypoglycemia (0.16+/-0.03 and 0.13+/-0.04 µmol/g/min, P = 0.14). However, the effect of GLP-1 on MGU was negatively correlated to baseline MGU both during normo- and hypoglycemia, (P = 0.006, r(2) = 0.64 and P = 0.018, r(2) = 0.64, respectively) and changes in MGU correlated positively with the level of insulin resistance (HOMA 2IR) during hypoglycemia, P = 0.04, r(2) = 0.54. GLP-1 mediated an increase in circulating glucagon levels at PG levels below 3.5 mM and increased glucose infusion rates during the hypoglycemia study. No differences in other circulating hormones or metabolites were found.
CONCLUSIONS:
While GLP-1 does not affect overall MGU, GLP-1 induces changes in MGU dependent on baseline MGU such that GLP-1 increases MGU in subjects with low baseline MGU and decreases MGU in subjects with high baseline MGU. GLP-1 preserves MGU during hypoglycemia in insulin resistant subjects. ClinicalTrials.gov registration numbers: NCT00418288: (hypoglycemia) and NCT00256256: (normoglycemia).
AuthorsMichael Gejl, Susanne Lerche, Annette Mengel, Niels Møller, Bo Martin Bibby, Kamille Smidt, Birgitte Brock, Hanne Søndergaard, Hans Erik Bøtker, Albert Gjedde, Jens Juul Holst, Søren Baarsgaard Hansen, Jørgen Rungby
JournalPloS one (PLoS One) Vol. 9 Issue 1 Pg. e83758 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24400077 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Glucose
  • Hormones
  • Fluorodeoxyglucose F18
  • Glucagon-Like Peptide 1
  • Glucose
Topics
  • Adult
  • Blood Glucose
  • Cross-Over Studies
  • Fluorodeoxyglucose F18 (metabolism)
  • Glucagon-Like Peptide 1 (pharmacology)
  • Glucose (metabolism)
  • Heart (drug effects)
  • Hormones (metabolism)
  • Humans
  • Hypoglycemia (diagnosis, metabolism)
  • Male
  • Metabolome
  • Myocardium (metabolism)
  • Positron-Emission Tomography
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: